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Abstract
Background and aims Aberrant crypt foci (ACF) are
preneoplastic lesions in animal models of colorectal cancer.
The aim of the study is to investigate if ACF are involved
in human colorectal carcinogenic process and if they can be
helpful in predicting the presence of a colorectal neoplasia.
Methods The study included, between 2003 and 2005, 182
patients, 62 with adenoma, 55 with colorectal carcinoma,
53 without colorectal lesions, and 12 with nonneoplastic
mucosal polyps. The number of rectal ACF was determined
by colonoscopy. Proliferation and apoptosis indexes were
evaluated by immunohistochemistry in rectal ACF, in
normal rectal mucosa, and in carcinomatous tissue.
Results The mean number of rectal ACF in patients with
rectal neoplasia was 12.64, significantly higher than in
patients with neoplastic lesions elsewhere in the colon (p=
0.01). The apoptosis index in ACF of patients with colorectal
carcinoma or adenoma aged 50 years or older was signifi-
cantly lower than in younger patients (1.3% vs 2.7%, p=0.01)
and, in patients with carcinoma, lower than in normal
mucosa (1.1% vs 2.1%, p=0.002). The proliferation index
was significantly higher in ACF of patients with colorectal
neoplasia aged less than 50 years than in normal mucosa
(10.9% vs 7.7%, p=0.02). The apoptosis index in ACF foci of
patients with carcinoma (1.1%) was significantly lower than
in patients without lesions (2.2%) and than in normal mucosa
(2%). The mean number of ACF is significantly higher in
patients with polyps larger than 1 cm (11.28 vs 6.27, p=0.02).
Conclusion Aberrant crypt foci probably precede the
appearance of neoplasia and may be helpful in predicting
the presence of a colorectal neoplastic lesion.
Keywords Colorectal cancer . Aberrant crypt foci .
Cell kinetics . Colonoscopy .Magnification . Chromoscopy
Introduction
Colorectal carcinoma (CRC) is one of the most commonly
diagnosed cancers, with a million new cases registered in
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2002 [1]. It is a lesion that can be prevented by adequate
screening measures, of which colonoscopy is the standard
method [2].
The carcinogenic pathway involves the accumulation of
genetic mutations in normal mucosa, determining phenotypic
modifications with biological and morphologic consequences
[3]. In this context, it is relevant to study the cellular kinetics
in the apparently normal colonic mucosa of patients with
CRC, as well as in individuals that present an increased risk
of CRC. Data about proliferation in normal colonic mucosa
of patients with adenomatous polyps are contradictory;
papers exist that show a higher proliferation rate than in
patients without colonic lesion [4–7], while others demon-
strate the contrary [8]. There seems to be no correlation
between the proliferation index in normal mucosa and the
capacity of predicting a neoplastic lesion in the future [6, 8].
When considering apoptosis, this is known to be significantly
less in the normal mucosa of patients with adenoma than in
controls [9, 10], and the proapoptotic response induced by
biliary acids in the normal mucosa is significantly smaller in
patients with a history of CRC than in individuals who are
neoplasia free [11]. These data about cellular kinetics in
normal mucosa should be interpreted cautiously because we
have to consider that supposedly “normal” mucosa is, in
reality, a heterogeneous entity. In fact, the known existence of
colonic and rectal aberrant crypt foci (ACF), variable in
number and histological nature, suggests that some of the
results reported in the literature on cellular kinetics may be
influenced by their presence in the biopsies selected for study.
Bird first described ACF in methylene-blue stained
whole mount preparations of rodent colon treated with a
colon carcinogen (azoxymethane) [12]. They are defined as
a group of one or more crypts that are larger than most
crypts in the field and have a thickened layer of epithelial
cells that stain more intensely with methylene-blue; they
often have a slit-shaped luminal opening, an increased
pericryptal space, and are elevated from the focal plane of
the microscope [13]. The assumption that ACF are
biomarkers of CRC has resulted from animal studies, which
show that colon carcinogens induce the appearance of ACF
[14] in a dose-related number [15]. The modulation of ACF
by chemopreventive agents with proven activity in CRC is
also described in animal studies [16–18]. With the
emergence of magnification and chromoscopy, it is now
possible to perform endoscopic in vivo human studies [19–
26]. Although there are a number of arguments supporting
the preneoplastic nature of ACF, such as an average number
that increases with age [23], a higher prevalence in patients
with neoplastic lesion of the colon [23], the identification of
ACF with carcinoma in situ in a patient with sporadic colon
cancer [27], the presence of ACF with dysplasia and APC
mutations in patients with familial adenomatous polyposis
[28, 29], and the occurrence of microsatellite instability in
ACF picked from patients with Lynch syndrome [30], the
truth is that doubt still persists with regard the preneoplastic
nature of ACF, which is unquestionable only in animal
models of intestinal cancer.
The aim of this study is to investigate whether ACF can
be considered precursors of the adenoma carcinoma
sequence. For this purpose, they were studied alongside
known CRC risk factors, in the vicinity of neoplastic
lesions in order to find out if their characteristics vary in
accordance with the distance to the colorectal neoplasia and
compared with normal colorectal mucosa and carcinoma-
tous tissue. The possibility that rectal ACF could predict the
presence of a colorectal neoplasia, maybe even contributing
to the stratification of the CRC risk, was also evaluated by
studying ACF characteristics in several groups of patients
with and without adenomas or carcinomas, as well as in
individuals without colorectal lesions.
Material and methods
The study included patients referred for colonoscopy at the
Department of Gastroenterology of the Coimbra University
Hospitals between January 2003 and July 2005. A sample
of 182 patients was evaluated, consisting of 106 males
(58.2%) and 76 females, with a mean age of 61.8 years and
a range of 23–89 years.
Inclusion criteria were the presence of colorectal
carcinoma, adenoma, or nonneoplastic mucosal colorectal
polyp, as well as patients without colorectal lesions. The
exclusion criteria were: pregnancy, age under 18 years,
personal or family history of familial adenomatous poly-
posis or of any other hereditary gastrointestinal polyposis
syndrome, Lynch Syndrome, inflammatory bowel disease,
previous intestinal resection, history of malignant neoplasia
submitted to radiotherapy or chemotherapy, hemorrhagic
diathesis, severe hepatic, cardiac or renal illness, use of
nonsteroid anti-inflammatory drugs, calcium, selenium,
folate, hormonal replacement therapy or ursodeoxycholic
acid in the preceding 3 months, and inclusion in post-
polypectomy colonoscopic surveillance protocol.
After giving signed informed consent, the patients were
subjected to an initial clinical evaluation to assess personal
and family history of colorectal neoplasia and alcohol and
tobacco consumption. With regard to family history of
colorectal cancer or adenomatous polyps, the patients were
classified into three classes according to criteria proposed
by Winawer et al. [31]: a first-degree relative with colon
cancer or adenomatous polyps diagnosed at age under
60 years or two first-degree relatives diagnosed with
colorectal cancer at any age (class 2), a first-degree relative
with colon cancer or adenomatous polyp diagnosed at age
over 60 years or two second-degree relatives with colorectal
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cancer (class 1), and absence of increased risk (class 0;
Table 2). Alcohol consumption habits were expressed in
grams of alcohol per day. In accordance with published data
[32, 33], the patients were classified into three groups: daily
intake of over 30 g of alcohol; daily intake of less than 30 g
of alcohol, and abstinence (when this exceeded 10 years).
Following the data from the literature [34], patients were
also classified according to the average number of
cigarettes smoked per day and divided into three groups:
daily intake of 20 cigarettes of more; daily intake of less
than 20 cigarettes; and nonsmokers (when abstinence from
smoking exceeded 10 years).
Colonoscopic procedure
Bowel preparation included ingesting 4 L of polyethylene
glycol solution. Colonoscopic examinations were per-
formed using two magnification colonoscopes (EC-485
ZW [Fujinon] and EC-3830 FZ [Pentax]), introduced as far
as the cecum. Appropriate endoscopic procedures were
performed in accordance with the findings, and the
morphology, size, number, and location of the lesions were
systematically documented.
Then patients underwent chromoscopy of the rectal
mucosa, defined as the segment, approximately 15 cm
long, from the dentate line to the rectosigmoid junction.
The procedure included the instillation, through a spray
catheter, of an average dose of 40 cm3 of 0.2% methylene-
blue, preceded by the instillation of about 10 cm3 of 10%
N-acetylcysteine followed by water wash to remove surface
mucus. Under magnification, ACF were defined as lesions
in which the crypts were more darkly stained with
methylene-blue than normal crypts and had larger diame-
ters, often with oval or slit-like lumens and thicker
epithelial linings [23] (Fig. 1). The total number of ACF
in rectal mucosa was counted as the procedure was
recorded.
The next step involved obtaining biopsy specimens with
ACF, at least two per patient. Finally, biopsy specimens
were also collected in rectal mucosa with normal endo-
scopic appearance under magnification (MNEA).
Immunohistochemistry
Proliferation and apoptosis were evaluated, using immuno-
histochemistry, in the ACF, MNEA, and carcinomatous
tissue obtained from colectomy specimens of surgically
resected carcinomas from ten patients (Fig. 2).
Proliferating cells were detected using the MIB-1
antibody (Ki-67 Antigen Kit, Novocastra Laboratories
Ltd., Newcastle upon Tyne, UK). Cells were counted as
positive if nuclear staining was present.
Apoptotic cells were detected using the M30 antibody
(M30 CytoDEATH, Roche Diagnostics GmbH, Penzberg,
Germany). Before staining with hematoxylin, each section
was incubated with the biotinylated secondary antibody
(rabbit antimouse, DakoCytomation Denmark A/S,
Glostrup, Denmark) and with streptavid-POD (Roche
Diagnostics GmbH, Penzberg, Germany). Cells were
counted as positive if cytoplasm staining was present.
For each specimen of ACF, MNEA, or carcinomatous
tissue, 1,000 randomly chosen epithelial cells were counted
using a light microscope (×400). The proliferation index
(PI; Ki-67 positive cells/total cells counted) and the
apoptotic index (AI; M30 positive cells/total cells counted)
were determined.
Statistical analysis
Statistical comparisons were made, in the case of categor-
ical variables, using the chi-squared test. Mean and
standard deviation were used for numerical variables, as
well as Bravais–Pearson correlation and the Student t test
for the evaluation of differences between means in two
Fig. 1 Endoscopic view of
aberrant crypt foci
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independent groups and in paired samples. A p<0.05 was
considered statistically significant. Statistical analysis was
performed with statistical software (SPSS version 11.5,
SPSS Inc, Chicago, IL, USA).
Results
The patients were divided into four groups according to the
endoscopic findings. Patients with more than one lesion
were classified on the basis of the most advanced lesion
found.
The group of patients with adenomatous polyps (Group
A) included 62 patients (34.1%), 35 male (56.5%) and 27
female, with a mean age of 59.9 years and a range of 23–
77 years (Table 1).
The group of patients with colorectal carcinoma (Group
B) included 55 patients (30.2%), 39 males (70.9%) and 16
females, with a mean age of 67.8 years and a range of 45–
89 years. The lesion was found in the left colon in 26
patients (47.3%), in the right colon in 18 (32.7%), and in
the rectum in 11 (20%).
The group of patients without colorectal lesions (Group
C) included 53 patients (29.1%), 31 females (58.5%) and
22 males, with a mean age of 59.8 years and a range of 27–
81 years.
The group of patients with nonneoplastic mucosal
polyps (Group D) included 12 patients (6.6%), ten males
(83.3%) and two females, with a mean age of 53.2 years
and a range of 29–70 years. The polyps were hyperplastic
in ten patients and juvenile in two.
The patients with carcinoma were predominantly male and
significantly older than patients from the other groups. Among
drinkers, the number of patients with adenomatous polyps was
higher, and in Group B, a larger proportion of patients had a
daily intake of over 30 g of alcohol. On the other hand, more
patients in Group D were nondrinkers (Table 2).
The number of rectal ACF was countable in only 178
patients. In the remaining four, difficulties in achieving a
good coloration of the rectal mucosa precluded a credible
calculation of the number of ACF (Table 3).
The mean number of rectal ACF observed per patient
was 7.35, with a range of 0–55. Twenty-nine patients
(16.2%) did not show any evidence of rectal ACF (nine
from Group A, nine from Group B, seven from Group C,
and four from Group D).
Eight hundred fourteen biopsy specimens with ACF
were collected—an average of five ACF per patient.
No significant correlation was found between age and
the number of ACF.
The AI was significantly lower in the ACF of patients
aged 50 years or over (p=0.035). The group classification
shows that the AI of the ACF was significantly lower
among patients with colorectal neoplasia (Groups A and B)
at age 50 or over when compared with younger patients
(1.3% SD 1.6 vs. 2.7% SD 2.8; p=0.01). The AI in the
ACF was higher than in the MNEA when the patients were
aged under 50 and lower when they were 50 or over. The
difference is significant when the group of patients with
carcinoma and aged 50 or over is considered (1.1% SD 1.5
vs 2.1% SD 2.0; p=0.002). The PI was significantly higher
in ACF when compared to MNEA among patients aged
Fig. 2 Proliferation in ACF (a) and in carcinoma (b); apoptosis in ACF (c) and in carcinoma (d); yellow arrow Ki67 expression; black arrow
M30 expression (×40 magnification)
Table 1 Patients with adenomatous polyps
Patient [n (%)]
Histology
High grade dysplasia 6 (9.7)
Villous 19 (30.6)
Tubulovillous 14 (22.6)
Tubular 23 (37.1)
Location
Right colona 1 (1.6)
Left colonb 46 (74.2)
Rectum 15 (24.2)
Number
More than two 5 (8.1)
Two 8 (12.9)
One 49 (79)
Size
Equal or superior to 1 cm 26 (41.9)
Inferior to 1 cm 36 (58.1)
a Cecum, ascending colon, hepatic flexure, and transverse colon
b Splenic flexure, descending colon, and sigmoid
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under 50 (p=0.002). The group classification shows that
this difference is significant (10.9% SD 12.4 vs 7.7% SD
9.1; p=0.02) among patients with colorectal neoplasia
(Groups A and B).
Although not statistically significant, it is noticeable that
the IP in the ACF is always higher than in MNEA in both
classes of drinkers, as well as in patients that report a family
history of colorectal neoplasia and that the IP is higher and
the IA lower than in MNEA in patients with a personal
history of colorectal neoplasia.
Although the average number of ACF in patients with
colorectal neoplasia is higher than in patients without
colorectal lesion, the difference is not statistically significant
(Table 4).
Table 2 The patients’ demographic and clinical characteristics
Groups (number of patients) p Value
A B C D Total
Age [Years (SD)] 59.9 (12.8) 67.8 (11.4) 59.8 (13.3) 53.2(12.7) 61.8(13.2) <0.0001
Gender [n (%)] M 35 (56.5) 39 (70.9) 22 (41.5) 10 (83.3) 106 (58.2) 0.005
F 27 (43.5) 16 (29.1) 31 (58.5) 2 (16.7) 76 (41.8)
Tobacco consumption [n (%)] 0 46 (74.2) 46 (83.6) 42 (79.2) 8 (66.7) 142 (78.02) NS
1 9 (14.5) 3 (5.5) 2 (3.8) 1 (8.3) 15 (8.24)
2 7 (11.3) 6 (10.9) 9 (17) 3 (25) 25 (13.74)
Alcohol consumption [n (%)] 0 18 (29) 19 (34.5) 33 (62.3) 4 (33.3) 74 (40.66) <0.0001
1 12 (19.4) 3 (5.5) 10 (18.9) 0 25 (13.74)
2 32 (51.6) 33 (60) 10 (18.9) 8 (66.7) 83 (45.6)
Family history [n (%)] 0 52 (83.9) 49 (89.1) 40 (75.5) 11(91.7) 152 (83.52) NS
1 3 (4.8) 3 (5.5) 4 (7.5) 0 10 (5.49)
2 7 (11.3) 3 (5.5) 9 (17) 1 (8.3) 20 (10.99)
Personal history [n (%)] 0 58 (93.5) 55 (100) 51 (96.2) 12 (100) 176 (96.7) NS
1 4 (6.5) 0 2 (3.8) 0 6 (3.3)
Total 62 55 53 12 182
M Male, F female; tobacco consumption: 0 nonsmokers, 1 daily intake of less than 20 cigarettes, 2 daily intake of 20 cigarettes or more; alcohol
consumption: 0 nondrinkers, 1 daily intake of less than 30 g of alcohol, 2 daily intake of over 30 g of alcohol; family history of colorectal
neoplasia: 0 absence, 1 one first-degree relative with colorectal neoplasia diagnosed at age over 60 years or two second-degree relatives with
CRC, 2 one first-degree relative with colorectal neoplasia diagnosed at age under 60 years or two first-degree relatives diagnosed with CRC at any
age, personal history of colorectal neoplasia: 0 absence, 1 presence; NS p≥0.05, SD standard deviation
Table 3 Mean number of ACF, mean IP and IA, in ACF and in MNEA, according to the patients’ demographic and clinical characteristics
Number of ACF (SD) PI (%) (SD) AI (%) (SD)
ACF MNEA ACF MNEA
Gender M 7.29 (8.62) 9.7 (8.5) 8.5 (8.3) 1.6 (1.9) 2.0 (2.4)
F 7.44 (6.04) 10.4 (9.4) 11.2 (9.0) 1.8 (2.2) 1.6 (2.0)
Age 0 7.64 (9.16) 12.6 (12.1)* 8.2 (8.9)* 2.8 (2.8)** 2.1 (2.5)
1 7.29 (7.29) 9.4 (8.0) 10 (8.6) 1.5 (1.8)** 1.8 (2.2)
Tobacco consumption 0 7.42 (7.93) 9.2 (8.5) 9.3 (8.5) 1.7 (2.0) 1.9 (2.2)
1 6.92 (6.96) 12.8 (11) 13.6 (9.7) 1.9 (2.4) 1.5 (1.8)
2 7.16 (6.30) 12.4 (9.5) 9.6 (8.9) 1.5 (1.9) 1.7 (2.6)
Alcohol consumption 0 7.68 (8.48) 10.4 (8.7) 10.8 (8.6) 1.5 (1.8) 2.4 (2.5)
1 8.62 (9.96) 11.6 (9.1) 10.1 (10) 2.5 (2.7) 1.4 (2.2)
2 6.66 (5.81) 9.1 (9.0) 8.5 (8.2) 1.6 (2.0) 1.6 (1.9)
Family history 0 7.41 (7.73) 9.4 (8.1) 9.6 (8.5) 1.7 (2.1) 1.9 (2.3)
1 5.66 (2.65) 14.7 (13.7) 11.6 (11.7) 1.5 (1.9) 1.3 (1.3)
2 7.33 (7.75) 11.9 (11.5) 9.3 (8.6) 1.5 (1.6) 1.5 (1.8)
Personal history 0 4.00 (2.44) 9.9 (8.9) 9.6 (8.5) 1.7 (2.1) 1.9 (2.3)
1 9.15 (8.02) 11.2 (8.8) 10.8 (12.2) 0.7 (0.9) 1.4 (1.4)
Age: 0 Under 50 years, 1 50 years or over
*PI in ACF in patients under 50 years vs PI in MNEA in patients under 50 years – p value below 0.05; **AI in ACF in patients under 50 years vs
AI in ACF in patients aged 50 years or over – p value below 0.05
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The AI was significantly lower in the ACF of patients
with carcinoma than in patients without colorectal lesion
(p=0.015). In those patients, the AI in ACF was signifi-
cantly lower than in the MNEA (p=0.002). Although not
statistically significant, it is clear that when comparing ACF
with MNEA, the IP is higher and the IA lower in the ACF.
The rectal location of the neoplasia is associated with a
significantly higher mean number of rectal ACF than when
the lesion is located elsewhere in the colon (p=0.01). A
similar result is found when considering only the patients
with adenoma (p=0.03). When the size of the polyp is 1 cm
or more, the mean number of ACF is significantly superior
when compared with patients with smaller lesions (p=
0.02). Although not statistically significant, it is noticeable
that the mean number of ACF is higher in patients with
more than two polyps and when a high risk of metachro-
nous advanced adenomas is present (Table 5).
The PI in ACF from patients with more than two polyps
is significantly higher than in patients with only one or two
polyps (p=0.02) and higher than MNEAwhen the adenoma
is located in the rectum (p=0.03). The AI in the ACF is
significantly lower when the adenoma is rectal (p=0.03).
In Group D, only the patients with hyperplastic lesions
presented rectal ACF. The mean number of rectal ACF in
those patients was 7.4.
The mean number of ACF was higher in patients whose
ACF presented a higher PI (p=0.04) and a lower AI (NS)
than in MNEA (Table 6).
When compared with ACF, carcinomatous tissue showed
a significantly higher PI (22% SD 16.1 vs 10.9% SD 9;
p=0.02) and AI (4% SD 2.5 vs 0.8% SD 0.9; p=0.003).
The cell kinetics in MNEA, ACF, and CRC is
summarized in Fig. 3.
Discussion
Although the patients included in the study came from a
referral center (a possible cause of selection bias), we
found, in agreement with published data [1, 36], that the
patients with carcinoma were older than those with
adenoma and that there was a male prevalence when a
colorectal neoplasia was present. Concerning alcohol
consumption habits, we found that colorectal neoplasia
occurrence was more frequent among drinkers and that
patients with carcinoma had a higher daily intake of
alcohol, which is also in agreement with recent published
papers [37–39].
The option to study only rectal ACF, in accordance with
studies that applied a similar methodology [19–26], deserves
some justification. This decision was founded on investiga-
tions in surgical specimens [40, 41] and endoscopic studies
[23, 42] that show that ACF are more frequently detected in
the left colon and in the rectum. We also thought that
characterizing the ACF with magnification and chromoscopy
in the whole colon in a large number of patients would
unacceptably prolong the examination time in some cases.
One feasible way to find out whether ACF can be
considered precursors of the adenoma carcinoma sequence
is to study their connection with known CRC risk factors.
Our results show that apoptosis is significantly reduced in
the ACF of patients with colorectal neoplasia aged over 50,
which suggests that the ability to grow is increased after
this age and supports the hypothesis that ACF are involved
in the carcinogenic process. In addition, proliferation is
significantly higher in ACF when compared with normal
mucosa among patients under 50 with colorectal neoplasia,
and apoptosis in ACF is lower than in the normal mucosa in
patients over 50 with carcinoma. This suggests that under
the age of 50, when adenomas prevail, the main process
involved in the genesis of the ACF is an increase in
proliferation, while after that age, possibly following
increased exposure to carcinogenic agents, the reduction
of apoptosis may lie at the core of the process.
Apoptosis and proliferation seem to be influenced by
other risk factors besides age. Although not statistically
significant, it is noticeable that proliferation in the ACF is
always higher than in normal mucosa in both classes of
drinkers, as well as in patients that report a family history of
colorectal neoplasia, while proliferation is higher and
apoptosis lower than in normal mucosa in patients with a
personal history of colorectal neoplasia. These data,
Table 4 Mean number of ACF, mean IP and IA, in ACF and in MNEA, according to patient group
Number of ACF (SD) PI (%) (SD) AI (%) (SD)
ACF MNEA ACF MNEA
Group A 8.4 (8.3) 8.6 (9.3) 8.9 (8.8) 1.8 (2.1) 1.5 (2.3)
Group B 7.8 (8.8) 10.0 (7.9) 9.5 (8.7) 1.1 (1.5)*,** 2.0 (2.0)**
Group C 5.9 (5.0) 11.3 (9.4) 11.2 (8.8) 2.2 (2.4)* 2.0 (2.3)
Group D 6.1 (7.0) 11.4 (8.7) 7.5 (6.0) 1.7 (2.2) 2.1 (3.2)
All patients 7.3 (7.6) 10.0 (8.9) 9.7 (8.7) 1.7 (2.0) 1.9 (2.2)
*AI in ACF in group B vs AI in ACF in group C – p value below 0.05; **AI in ACF in group B vs AI in MNEA in group B – p value below 0.05
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suggesting a parallel between cell kinetics in ACF and risk
factors for CRC, reinforce the hypothesis that ACF are
preneoplastic.
The possible association between ACF and colorectal
neoplasia can also be evaluated by their study in the
vicinity of neoplastic lesions. As only rectal ACF were
considered in this study, their characterization in patients
with rectal neoplasia is crucial. The mean number of ACF
in patients with rectal neoplasia is significantly higher
than in patients with lesions located elsewhere in the
colon, a result that is similar when only patients with
adenoma are considered. The connection between rectal
ACF and rectal neoplastic lesions is further supported by
the significantly higher proliferation index found in the
ACF when compared with normal mucosa in patients with
rectal lesions and the significantly lower apoptotic index
detected in the ACF of these patients. Such findings
suggest that the rectal neoplastic lesions might have
evolved from one or more of the rectal ACF. This
possibility is sustained by the concept of field cancer-
Table 6 Average number of ACF according to AI and PI in ACF vs MNEA
PI (%) (SD) AI (%) (SD)
ACF > MNEA ACF ≤ MNEA ACF < MNEA ACF ≥ MNEA
Number of ACF(SD) 10.1 (9.4)* 7.6 (5.2)* 8.9 (8.3) 8.5 (6.9)
*Number of ACF when PI in ACF is higher than in MNEA vs number of ACF when PI in ACF is lower than in MNEA – p value below 0.05
Table 5 Mean number of ACF, mean IP and IA, in ACF and in MNEA in patients with neoplastic lesions (Groups A and B) and with adenomas
(Group B)
Number of ACF (SD) PI (%) (SD) AI (%) (SD)
ACF MNEA ACF MNEA
Neoplastic lesions
Location
Right colon 6 (5.67)* 10.5 (8.2) 9.5 (9.6) 1.4 (1.7) 2.3 (2.0)
Left colon 7 (6.09)* 9.0 (8.5) 9.9 (8.9) 1.6 (2.0) 1.6 (2.1)
Rectum 12.64 (13.62)* 9.0 (9.6)** 6.8 (7.7)** 1.2 (1.5) 1.8 (2.4)
Adenomas
Location
Left colon 6.44 (5.7)*** 8.7 (8.7) 9.8 (8.9) 2.2 (2.3)**** 1.7 (2.4)
Rectum 14.35 (12.1)*** 9.1 (11.3) 6.9 (8.4) 0.8 (0.7)**** 1.3 (2.1)
Histology
High grade dysplasia 9.33 (8.59) 6.2 (8.5) 3.5 (3.1) 2.2 (2.9) 0.2 (0.3)
Villousa 7.0 (9.17) 10.1 (10.6) 11.0 (10.2) 1.6 (1.8) 1.9 (2.4)
Tubular 10.45 (6.59) 7.5 (8.0) 7.8 (7.4) 1.9 (2.2) 1.4 (2.3)
Number
More than two 17.25 (19.9) 18.1(14.3)***** 18.5 (10.1) 2.4 (2.0) 3.3 (2.5)
Two 6.8 (8.23) 5.5 (6.0)***** 7.0 (11.0) 1.3 (1.8) 0.2 (0.2)
One 7.93 (6.5) 7.9 (8.3)***** 8.0 (7.8) 1.8 (2.1) 1.5 (2.3)
Dimension
Equal or superior to 1 cm 11.28 (10.36)****** 8.8 (10.1) 9.1 (10.3) 1.5 (1.8) 1.1 (1.4)
Inferior to 1 cm 6.27 (5.64)****** 8.6 (8.8) 8.7 (7.5) 2.1 (2.3) 1.9 (2.8)
Metachronous lesion
High riskb 8.53 (8.90) 8.8 (9.8) 8.5 (8.4) 1.8 (1.9) 1.5 (2.0)
Reduced risk 7.88 (4.31) 8.1 (8.3) 9.9 (10.2) 1.8 (2.6) 1.6 (3.0)
a Includes villous and tubulovillous adenoma
bHigh risk of metachronous advanced adenomas: more than two adenomas, adenoma equal or larger than 1 cm, villous histology or high-grade
dysplasia or family history of CRC [35]
*Number of ACF in patients with rectal neoplastic lesions vs number of ACF in patients with neoplastic lesions in the left and right colon –
p value below 0.05; **PI in ACF in patients with rectal adenomas vs PI in MNEA in patients with rectal adenomas – p value below 0.05;
***Number of ACF in patients with rectal adenomas vs number of ACF in patients with adenomas in the left colon – p value below 0.05; ****AI
in ACF in patients with rectal adenomas vs AI in ACF in patients with adenomas in the left colon – p value below 0.05; *****PI in ACF in
patients with more than two adenomas vs PI in patients with one or two adenomas – p value below 0.05; ******Number of ACF in patients with
adenomas larger than 1 cm vs number of ACF in patients with adenomas inferior to 1 cm – p value below 0.05
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ization, put forward to explain the development of
multiple primary tumors and locally recurrent cancer,
and assuming that multiple areas with similar biological
alterations exist in the neighborhood of the carcinomas
[43]. These areas, defined for Braakhuis et al. [44] as
preneoplastic, are epithelial in nature and, like ACF, of
monoclonal origin [45] and may, under certain circum-
stances, progress to neoplasia.
The evaluation of the rectal ACF according to the
pathological findings, namely the presence or absence of
colorectal neoplasia, might be relevant because it could
help predict the existence of a neoplastic lesion. A
comparison of the results of the different series published
shows a common trend, in spite of some differences. In
fact, Takayama et al. [23], Adler et al. [19], and Yokota et
al. [24] found a higher mean number of ACF in patients
with benign and malignant colorectal neoplasia than in
patients without endoscopic lesions. The paper by Hurl-
stone et al. [20] on ACF in patients with flat lesions reports
similar results, demonstrating that the mean number of ACF
increases when patients without lesion, with adenoma, and
with carcinoma are considered in succession. In our series,
the trend is also toward the presence of a higher mean
number of ACF in patients with neoplasia (malignant and
benign) than in patients without lesion or with nonneo-
plastic mucosal polyps.
The link between rectal ACF and colorectal pathology is
strengthened when the group of patients with adenoma is
stratified according to the characteristics of the polyps. Indeed,
the mean number of ACF is significantly higher in patients
with bigger polyps. Takayama et al. [23] and Hurlstone et al.
[20] found a significant correlation only with the number of
polyps. In our series, the mean number of ACF is also higher
in patients with more polyps and at high risk of presenting
metachronous advanced adenomas, although this is not
statistically significant. Proliferation in ACF is higher in
patients with bigger polyps and at high risk of metachronous
advanced adenomas, the difference being statistically signif-
icant in patients with more than two polyps. These results
suggest that the characterization of rectal ACF might be
useful in stratifying the risk of neoplasia and in postpoly-
pectomy colonoscopic surveillance protocols.
The apoptotic index is related to the presence of
colorectal carcinoma. In fact, in patients with this patho-
logical finding, apoptosis in the ACF is significantly lower
than in patients without lesion and lower than in normal
mucosa. As rectal ACF cannot be implicated in the genesis
of neoplastic lesions not located in the rectum, one possible
explanation is that carcinogenic agents tend to accumulate
in the rectum. Indeed, it is possible to speculate that while
the carcinogenic agents act along the entire bowel,
eventually contributing to the appearance of the neoplastic
tissue, they finally accumulate in the rectum, causing the
increase in the number of ACF. This parallel, which is in
agreement with the results reported by Seike et al. [25],
might mean that rectal ACF could be an indicator of a
carcinoma elsewhere in the colon.
The way luminal carcinogenic agents reach cells with
higher proliferative activity, deeply located in the crypts, is
not yet fully understood. Our results, showing that apoptosis
in the ACF of patients with carcinoma is significantly lower
than in normal mucosa and in patients without colorectal
lesion reveals a disturbance in cell kinetics that probably
allows cells to remain longer in the upper parts of the crypts,
increasing the probability of a luminal carcinogenic agent
initiating an advantageous mutation. The results reported by
Shpitz et al. [46], according to which the cells in the upper
third of ACF maintain a significantly higher proliferative
activity than in the same location in normal mucosa, seem
to support this hypothesis.
The literature is scarce about ACF in nonneoplastic
mucosal polyps, namely of the hyperplastic type. In spite of
the small number of patients with this type of polyp
considered in our series, it is clear that rectal ACF are also
present in patients with hyperplastic polyps.
In our series, when comparing all the ACF analyzed with
normal mucosa, proliferation is higher and apoptosis lower
(though not statistically significant), a trend that is in
accordance with published studies [47, 48]. It might be
necessary to increase the sample size or stratify the study
according to the crypt compartments to achieve statistical
significance.
As expected, a higher proliferation index in the ACF
than in the normal mucosa is associated with a significantly
higher mean number of ACF. A lower apoptotic index in
the ACF is also linked with a higher mean number of ACF.
This connection between cell kinetics and the mean number
of ACF confers credibility on the endoscopic technique of
detection and counting of rectal ACF.
It is a known fact that proliferation is higher in
carcinomatous tissue than in normal mucosa or in ACF
[48]. With regard to apoptosis, contradictory results are
found when carcinomas and adenomas are compared; some
papers report a decrease [49, 50] and some an increase [51].
Our study shows that both proliferation and apoptosis are
significantly higher in carcinoma than in ACF. The
increased apoptosis could be the result of the lack of
PI MNEA ACF CRC 
AI MNEA ACF CRC 
NS p < 0,05 
p < 0,05 p < 0,05 
P <  0,05 
P < 0,05 
Fig. 3 Cell kinetics in MNEA, ACF, and CRC
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nutrients and oxygen caused by the fast growth of the
lesion [52]. The apparent discrepancy between the exis-
tence of malignant tissue and a rise in apoptosis may be
explained by a proportionally lesser increase when com-
pared with proliferation [51].
In our series, different results were obtained when we
compared proliferation and apoptosis in ACF with normal
mucosa and carcinoma. In fact, while apoptosis significant-
ly decreases and proliferation increases in ACF compared
to normal mucosa, apoptosis and proliferation are signifi-
cantly higher in carcinoma versus ACF. Given these data,
we can speculate that the main disturbance in cell kinetics
involved in the progression from normal mucosa to ACF is
a decrease in apoptosis, while the admitted progression of
the ACF to CRC could be the result of a marked increase in
proliferation accompanied by a proportionately inferior
increase in apoptosis unable to prevent the tumor growth.
The reports of a progressive increase in proliferative
activity accompanied, in the final phase of the carcinogen-
esis, by a significant increase in apoptosis [48, 51] is in
agreement with our results, reinforcing the hypothesis that
ACF are part of the carcinogenic process.
In conclusion, the results of our study, by showing that
the number and cell kinetics of the ACF vary according
with the vicinity of neoplastic lesion and with known risk
factors for colorectal cancer, namely age, support the
assumption that ACF are preneoplastic. Rectal ACF
characterization may be helpful in predicting the presence
of a colorectal neoplasia because there is a tendency
towards a higher mean number of ACF in patients with
neoplasia; patients with polyps bigger than 1 cm present
significantly more rectal ACF, and in patients with
carcinoma, irrespective of the location of the lesion, the
rectal ACF apoptotic index is lower than in the normal
mucosa and in patients without colorectal lesions.
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